标签归档：tfa

FTI 276 TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FTI 276 TFA  纯度: 98.06%

FTI-276 是一种有效的 protein farnesyl transferase (PFT) 抑制剂, 作用于恶性疟原虫和人类的 IC50 值分别为 0.9 nM 和 0.5 nM。

FTI 276 TFA

FTI 276 TFA Chemical Structure

CAS No. : 1217471-51-6

规格 价格 是否有货
10 mM * 1 mL in DMSO ￥4820 询问价格 & 货期
5 mg ￥4000 询问价格 & 货期
10 mg ￥6800 询问价格 & 货期
25 mg ￥13500 询问价格 & 货期
50 mg ￥22000 询问价格 & 货期

* Please select Quantity before adding items.

FTI 276 TFA 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Covalent Screening Library
  • Anti-Pancreatic Cancer Compound Library

生物活性

FTI-276 is a protein farnesyl transferase (PFT) inhibitor with IC50s of 0.9 nM and 0.5 nM for Plasmodium falciparum and human, respectively[1].

IC50 & Target

IC50: 0.9 nM (PFT, Plasmodium falciparum), 0.5 nM (PFT, human)[1].
分子量

547.61

Formula

C23H28F3N3O5S2
CAS 号

1217471-51-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (182.61 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8261 mL 9.1306 mL 18.2612 mL
5 mM 0.3652 mL 1.8261 mL 3.6522 mL
10 mM 0.1826 mL 0.9131 mL 1.8261 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.57 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.57 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.57 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Chakrabarti D, et al. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum.J Biol Chem. 2002 Nov 1; 277(44):42066-73. Epub 2002 Aug 22.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CGGRGD TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CGGRGD TFA 

CGGRGD TFA，一种以半胱氨酸为 N 端的 RGD 衍生物。CGGRGD TFA 通过固相肽合成技术合成的，PCL 纤维的表面被氨基2-氰基苯并噻唑氨解，然后加入 2-氰基苯并噻唑 (CBT)。

CGGRGD TFA

CGGRGD TFA Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CGGRGD TFA, a RGD derivative with cysteine as its N-terminal, CGGRGD TFA is synthesized via solid-phase peptide synthesis technique and the surface of PCL fibers is aminolysised by amino 2-cyanobenzothiazole followed by the addition of 2-cyanobenzothiazole (CBT)[1].

体外研究
(In Vitro)

CGGRGD TFA is a characteristic sequence of fifibronectin that binds to the receptors on cell surface. (PCL) is a popular materials for tissue engineering due to its optimal biocompatibility, biodegradability, and thermoplastic characteristics[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

677.61

Formula

C21H34F3N9O11S
Sequence

Cys-Gly-Gly-Arg-Gly-Asp
Sequence Shortening

CGGRGD
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wenting Zhen, et al.Functionalization of PCL fibrous membrane with RGD peptide

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

ACTH (1-17) (TFA)(Synonyms: α1-17-ACTH TFA)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

ACTH (1-17) (TFA) (Synonyms: α1-17-ACTH TFA)

ACTH (1-17) TFA 是促肾上腺皮质激素类似物，是一种有效的人黑皮素受体 (human melanocortin 1 (MC1) receptor) 激动剂，Ki 值为 0.21 nM。

ACTH (1-17) (TFA)(Synonyms: α1-17-ACTH TFA)

ACTH (1-17) (TFA) Chemical Structure

规格 价格 是否有货
1 mg ￥1300 询问价格 & 货期
5 mg ￥4500 询问价格 & 货期
10 mg ￥6500 询问价格 & 货期

* Please select Quantity before adding items.

ACTH (1-17) (TFA) 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Neuronal Signaling Compound Library
  • Anti-Cancer Compound Library
  • Endocrinology Compound Library
  • Anti-Obesity Compound Library
  • Targeted Diversity Library

生物活性

ACTH (1-17) TFA, an adrenocorticotropin analogue, is a potent human melanocortin 1 (MC1) receptor agonist with a Ki of 0.21 nM.

IC50 & Target

Ki: 0.21 nM (human MC1 receptor)[1]
体外研究
(In Vitro)

ACTH (1-17) TFA is a potent agonist at the hMC1R. ACTH (1-17) shows high affinity for the hMC1R with a Ki value of 0.21±0.03 nM which is slightly higher than that of 0.13±0.005 nM for alpha-MSH[1]. ACTH (1-17) induces a slight and not significant increase in growth hormone secretion even when micromolar concentrations of the peptide are employed in rat pituitary cultures[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Inhibition of DNA labeling is noted when the ACTH (1-17) is administered at 2 hr after the beginning of the daily dark span when nocturnal animals become active. When administered at this circadian stage, the larger dose in particular is associated with an inhibition of DNA labeling lasting for 24 hr. The inhibitory effect is much shorter when the same dose is injected 4 hr earlier[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

2207.43

Formula

C95H145N29O23S.C2HF3O2
Sequence

Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg
Sequence Shortening

SYSMEHFRWGKPVGKKR
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture and light

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Tsatmali M et al. ACTH1-17 is a more potent agonist at the human MC1 receptor than alpha-MSH. Cell Mol Biol (Noisy-le-grand). 1999 Nov;45(7):1029-34.

    [2]. Ceda GP, et al. The effects of ACTH (1-17) on GH secretion in vitro. Horm Metab Res. 1987 Aug;19(8):361-3.

    [3]. Walker WV, et al. Effect of an adrenocorticotropin analogue, ACTH (1-17), on DNA synthesis in murine metaphyseal bone. Biochem Pharmacol. 1985 Apr 15;34(8):1191-6.
Cell Assay
[1]

Rat pituitary cells are incubated in the presence of varying concentrations of ACTH (1-17) (0.1 nM-1 μM). A significant increase of growth hormone secretion is documented with each concentration[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[3]

Mice[3]

The effects of ACTH (1-17) on the rate of DNA labeling in the metaphyseal bone of CD2F1 mice are tested on a chronopharmacological dosing schedule. Groups of mice that has been conditioned to a 12-hr light/12-hr dark schedule are injected at one of six different timepoints, 4 hr apart during ,a single 24-hr span with either a low (0.021 I.U/kg) or a high (20 I.U./kg) dose of ACTH (1-17). Control groups receive injections of a placebo at corresponding timepoints. Subgroups of mice are injected with [3H]thymidine ([3H]Tdr) to follow the changes in DNA labeling in the proximal tibial metaphysis at 15 min and 2, 4, 8, 12 and 24 hr after ACTH (1-17) or placebo treatment[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Tsatmali M et al. ACTH1-17 is a more potent agonist at the human MC1 receptor than alpha-MSH. Cell Mol Biol (Noisy-le-grand). 1999 Nov;45(7):1029-34.

    [2]. Ceda GP, et al. The effects of ACTH (1-17) on GH secretion in vitro. Horm Metab Res. 1987 Aug;19(8):361-3.

    [3]. Walker WV, et al. Effect of an adrenocorticotropin analogue, ACTH (1-17), on DNA synthesis in murine metaphyseal bone. Biochem Pharmacol. 1985 Apr 15;34(8):1191-6.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SAH-SOS1A TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SAH-SOS1A TFA  纯度: 99.37%

SAH-SOS1A TFA 是一种基于肽的 SOS1/KRAS 蛋白相互作用抑制剂。SAH-SOS1A TFA 以纳摩尔亲和力 (EC50=106-175 nM) 与野生型和突变型 KRAS (G12D, G12V, G12C, G12S, Q61H) 结合，直接和独立地阻断核苷酸结合。SAH-SOS1A TFA 损害 KRAS 驱动的癌细胞活力，并通过阻断 KRAS 下游 ERK-MAPK 磷酸化信号级联的机制发挥作用。

SAH-SOS1A TFA

SAH-SOS1A TFA Chemical Structure

规格 价格 是否有货 数量
5 mg ￥4200 In-stock
10 mg ￥7000 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

SAH-SOS1A TFA 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS[1].

IC50 & Target

KRAS-SOS1

 

KRas G12C

140 nM (EC50)

KRas G12D

109 nM (EC50)

KRas G12V

154 nM (EC50)

KRas G12S

155 nM (EC50)

KRas Q61H

175 nM (EC50)

K-Ras WT

106 nM (EC50)

体外研究
(In Vitro)

SAH-SOS1A TFA (0.625-40 μM; 24 hours) dose-responsively impairs the viability of cancer cells bearing G12D, G12C, G12V, G12S, G13D, and Q61H mutations with IC50 values in the 5- to 15-μM range. Cancer cells expressing wild-type KRAS, such as HeLa and Colo320-HSR cells, are similarly affected[1].
SAH-SOS1A TFA (5-40 μM; 4 hours) dose-responsively inhibits MEK1/2, ERK1/2, and AKT phosphorylation[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Panc 10.05 cells bearing the KRAS G12D mutation
Concentration: 0.625-40 μM
Incubation Time: 24 hours
Result: Dose-responsively impaired the viability of cancer cells bearing KRAS G12D.

Western Blot Analysis [1]

Cell Line: Panc 10.05 cells
Concentration: 5-40 μM
Incubation Time: Indicated doses for 4 h, followed by 15-min stimulation with EGF
Result: Dose-responsively inhibited MEK1/2, ERK1/2, and AKT phosphorylation.

体内研究
(In Vivo)

SAH-SOS1A (0.2 μL of 10 mM solution; injection; 48 hours; abdomens of D. melanogaster Ras85DV12/ActinGS) treatment notably decreases the phosphorylation state of ERK1/2[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

2301.55

Formula

C102H160N27F3O30
Sequence

Arg-Arg-Phe-Phe-Gly-Ile-Aaa-Leu-Thr-Asn-Aaa-Leu-Lys-Thr-Glu-Glu-Gly-Asn (Covalent bridge:Aaa7-Aaa11)
Sequence Shortening

RRFFGI{Aaa}LTN{Aaa}LKTEEGN (Covalent bridge:Aaa7-Aaa11)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Protect from light, stored under nitrogen

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
溶解性数据
In Vitro: 

H2O : 33.33 mg/mL (14.48 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.4345 mL 2.1724 mL 4.3449 mL
5 mM 0.0869 mL 0.4345 mL 0.8690 mL
10 mM 0.0434 mL 0.2172 mL 0.4345 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Leshchiner ES, et al. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. Proc Natl Acad Sci U S A. 2015;112(6):1761-1766.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

KKI-5 (TFA)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

KKI-5 (TFA)  纯度: 99.93%

KKI-5 (TFA) 是一种特异性的组织激肽释放酶 (kallikrein) 抑制剂。KKI-5 (TFA) 可降低乳腺癌细胞浸润。

KKI-5 (TFA)

KKI-5 (TFA) Chemical Structure

规格 价格 是否有货 数量
1 mg ￥750 In-stock
5 mg ￥2250 In-stock
10 mg ￥3950 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

KKI-5 (TFA) 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

KKI-5 (TFA) is a specific inhibitor of tissue kallikrein. KKI-5 (TFA) can attenuate breast cancer cell invasion[1].

IC50 & Target

Kallikrein[1]
分子量

887.90

Formula

C37H56F3N11O11
Sequence

Ac-Pro-Phe-Arg-Ser-Val-Gln-NH2
Sequence Shortening

Ac-PFRSVQ-NH2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

H2O : 9.09 mg/mL (10.24 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1263 mL 5.6313 mL 11.2625 mL
5 mM 0.2253 mL 1.1263 mL 2.2525 mL
10 mM 0.1126 mL 0.5631 mL 1.1263 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Deshpande MS, et al. Mapping the binding site of tissue kallikrein: preparation and testing of all possible substrate analog inhibitors homologous with the sequence of kininogen between Ser386 and Gln392. J Med Chem. 1992 Aug 21;35(17):3094-102.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

α-Factor Mating Pheromone, yeast TFA(Synonyms: Mating Factor α TFA)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

α-Factor Mating Pheromone, yeast TFA (Synonyms: Mating Factor α TFA)

α-Factor Mating Pheromone, yeast (TFA) 是一种十三肽，由 S. cerevisiae 的 α 细胞分泌产生，通过 Ste2p 受体起作用。

α-Factor Mating Pheromone, yeast TFA(Synonyms: Mating Factor α TFA)

α-Factor Mating Pheromone, yeast TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ￥800 In-stock
5 mg ￥2800 In-stock
10 mg ￥4800 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

生物活性

α-Factor Mating Pheromone, yeast (TFA) is a tridecapeptide secreted by S. cerevisiae α cells via Ste2p receptor[1].

分子量

1798.02

Formula

C84H115N20F3O19S
Sequence

Trp-His-Trp-Leu-Gln-Leu-Lys-Pro-Gly-Gln-Pro-Met-Tyr
Sequence Shortening

WHWLQLKPGQPMY
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture and light

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. [1]. Naider F, et al. The alpha-factor mating pheromone of Saccharomyces cerevisiae: a model for studying the interaction of peptide hormones and G protein-coupled receptors. Peptides. 2004 Sep;25(9):1441-63.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Gp100 (25-33), mouse TFA(Synonyms: Mgp100 (25-33) (TFA))

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Gp100 (25-33), mouse TFA (Synonyms: Mgp100 (25-33) (TFA)) 纯度: 99.25%

Gp100 (25-33), mouse TFA 序列位于小鼠自身/肿瘤抗原糖蛋白 (Mgp100) 的第25-33个残基。Mgp100 (25-33), mouse是一种参与色素合成的酶，其表位片段在正常黑色素细胞和黑色素瘤细胞中均有表达。

Gp100 (25-33), mouse TFA(Synonyms: Mgp100 (25-33) (TFA))

Gp100 (25-33), mouse TFA Chemical Structure

规格 价格 是否有货 数量
10 mg ￥2850 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Gp100 (25-33), mouse TFA 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

Gp100 (25-33), mouse TFA sequence is found in residues 25 to 33 of the mouse self/tumor antigen glycoprotein (mgp100). Mgp100 is an enzyme involved in pigment synthesis, and the epitope fragment is expressed in both normal melanocytes and melanoma cells[1].

分子量

1218.15

Formula

C48H70F3N15O19
Sequence Shortening

EGSRNQDWL
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture and light

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
参考文献

  • [1]. Gal Cafri, et al. Production of LacZ inducible T cell hybridoma specific for human and mouse gp100 25-33 peptides. PLoS One. 2013;8(2):e55583.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CMD178 TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CMD178 TFA  纯度: 98.72%

CMD178 TFA 是一种先导肽，能够持续地通过抑制 IL-2/s IL-2Rα 信号通路来减少 Foxp3 和 STAT5 的表达，并可抑制 Treg 细胞的发育。

CMD178 TFA

CMD178 TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ￥3500 In-stock
5 mg ￥6500 In-stock
10 mg ￥10500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

CMD178 TFA 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development[1].

体外研究
(In Vitro)

CMD178 TFA (100 mM) suppresses IL-2-induced STAT5 phosphorylation and inhibits Foxp3 expression in T cells[1].
CMD178 TFA (100 mM) inhibits the development of Treg cells induced by IL2/sIL-2Rα signaling[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

964.05

Formula

C9H8F5KO3Y
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
参考文献

  • [1]. Price-Troska T, et, al. Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides. Invest New Drugs. 2019 Feb;37(1):9-16.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Thalidomide-O-amido-PEG2-C2-NH2 TFA(Synonyms: Cereblon Ligand-Linker Conjugates 10 TFA; E3 Ligase Ligand-Linker Conjugates 24 TFA)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Thalidomide-O-amido-PEG2-C2-NH2 TFA (Synonyms: Cereblon Ligand-Linker Conjugates 10 TFA; E3 Ligase Ligand-Linker Conjugates 24 TFA) 纯度: 99.52%

Thalidomide-O-amido-PEG2-C2-NH2 TFA 是一种合成的 E3 连接酶配体-linker 偶联物，包含基于 Thalidomide 的 cereblon 配体和 2 个单元的 PEG linker。

Thalidomide-O-amido-PEG2-C2-NH2 TFA(Synonyms: Cereblon Ligand-Linker Conjugates 10 TFA; E3 Ligase Ligand-Linker Conjugates 24 TFA)

Thalidomide-O-amido-PEG2-C2-NH2 TFA Chemical Structure

CAS No. : 1957235-75-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
100 mg ￥3500 In-stock
500 mg ￥13500 In-stock
1 g ￥25000 In-stock
2 g ￥35000 In-stock
5 g   询价  
10 g   询价  

* Please select Quantity before adding items.

生物活性

Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

IC50 & Target

Cereblon

 

体外研究
(In Vitro)

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

576.48

Formula

C23H27F3N4O10
CAS 号

1957235-75-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

H2O : 150 mg/mL (260.20 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7347 mL 8.6733 mL 17.3467 mL
5 mM 0.3469 mL 1.7347 mL 3.4693 mL
10 mM 0.1735 mL 0.8673 mL 1.7347 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. ARYL SULFONOHYDRAZIDES. WO 2017/176958 A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Thalidomide-O-amido-C6-NH2 TFA(Synonyms: Cereblon Ligand-Linker Conjugates 11 TFA; E3 Ligase Ligand-Linker Conjugates 25 TFA)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Thalidomide-O-amido-C6-NH2 TFA (Synonyms: Cereblon Ligand-Linker Conjugates 11 TFA; E3 Ligase Ligand-Linker Conjugates 25 TFA) 纯度: 99.82%

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) 是一种合成的 E3 连接酶配体-linker 偶联物，包含基于 Thalidomide 的 cereblon 配体和 1 个 linker。可用于合成 PROTAC 分子。

Thalidomide-O-amido-C6-NH2 TFA(Synonyms: Cereblon Ligand-Linker Conjugates 11 TFA; E3 Ligase Ligand-Linker Conjugates 25 TFA)

Thalidomide-O-amido-C6-NH2 TFA Chemical Structure

CAS No. : 1950635-14-9

规格 价格 是否有货 数量
100 mg ￥3500 In-stock
500 mg ￥13500 In-stock
1 g ￥25000 In-stock
2 g ￥35000 In-stock
5 g   询价  
10 g   询价  

* Please select Quantity before adding items.

生物活性

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs[1].

IC50 & Target

Cereblon

 

体外研究
(In Vitro)

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

544.48

Formula

C23H27F3N4O8
CAS 号

1950635-14-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
溶解性数据
In Vitro: 

DMSO : ≥ 105.5 mg/mL (193.76 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8366 mL 9.1831 mL 18.3661 mL
5 mM 0.3673 mL 1.8366 mL 3.6732 mL
10 mM 0.1837 mL 0.9183 mL 1.8366 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Bradner J, et al. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses. WO 2017024318 A1

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

MM-589 TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

MM-589 TFA  纯度: 98.76%

MM-589 TFA 是 WD 重复结构域 5 (WDR5) 和混合谱系白血病 (MLL) 蛋白-蛋白相互作用的有效抑制剂。MM-MM-589 TFA 结合 WDR5 的 IC50 为 0.90 nM。抑制 MLL H3K4 甲基转移酶活性的 IC50 为 12.7 nM。

MM-589 TFA

MM-589 TFA Chemical Structure

CAS No. : 2097887-21-1

规格 价格 是否有货 数量
1 mg ￥12000 In-stock
2 mg ￥18000 In-stock
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

MM-589 TFA 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus

生物活性

MM-589 TFA is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM[1].

IC50 & Target

IC50: 0.90 nM (WDR5), 12.7 nM (HMT)[1]

Ki: <1 nm (wdr5)[1]
体外研究
(In Vitro)

MM-589 (0.01-10 µM, 4 days or 7 days) potently and selectively inhibits cell growth in human leukemia cell lines harboring MLL translocations[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MV4-11 and MOLM-13 cells
Concentration: 0.01, 0.1, 1, 10 μM
Incubation Time: 4 days or 7 days
Result: Potently inhibited MV4-11 and MOLM-13 cell growth with IC50s of 0.25 and 0.21 μM, respectively. Had much weaker activity in the inhibition of cell growth of the HL-60 cell line with an IC50 of 8.6 μM.

分子量

686.72

Formula

C30H45F3N8O7
CAS 号

2097887-21-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
参考文献

  • [1]. Karatas H, et al. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction. J Med Chem. 2017 Jun 22;60(12):4818-4839.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

AUNP-12 TFA(Synonyms: NP-12 TFA)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

AUNP-12 TFA (Synonyms: NP-12 TFA) 纯度: ≥96.0%

AUNP-12 (NP-12) TFA 是 PD-1 信号通路的一种多肽拮抗剂，在抑制淋巴细胞增殖和效应功能方面对 PD-L1 和 PD-L2 具有等效的拮抗作用。AUNP-12 TFA 具有免疫激活作用、良好的抗肿瘤活性，具有更好的研究免疫相关不良事件 (irAEs) 的潜力。

AUNP-12 TFA(Synonyms: NP-12 TFA)

AUNP-12 TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ￥1300 In-stock
5 mg ￥3400 In-stock
10 mg ￥5600 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

AUNP-12 TFA 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs)[1].

IC50 & Target

PD-1 signaling pathway[1]
体外研究
(In Vitro)

NP-12 TFA displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions [1].
NP-12 TFA rescues the proliferation in the mouse splenocyte assay system with average EC50 values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively [1].
NP-12 TFA is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC50 values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively [1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

3375.57

Formula

C5H17TFIN2O2S2Si
Sequence Shortening

H-SNTSESFKF(H-SNTSESF)RVTQLAPKAQIKE-NH2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
参考文献

  • [1]. Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

GPLGIAGQ TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

GPLGIAGQ TFA  纯度: 99.67%

GPLGIAGQ TFA 是一种 MMP2 可降解 (cleavable) 的多肽，在脂质体和胶束纳米载体中都被用作刺激敏感的连接物，用于 MMP2 触发的肿瘤靶向研究。GPLGIAGQ可用于合成光动力疗法 (PDT) 中独特的MMP2靶向光敏剂。

GPLGIAGQ TFA

GPLGIAGQ TFA Chemical Structure

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1360 In-stock
5 mg ￥1000 In-stock
10 mg ￥1500 In-stock
50 mg ￥3500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

GPLGIAGQ TFA 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Peptide Library

生物活性

GPLGIAGQ TFA, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting. GPLGIAGQ TFA can be used to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy (PDT)[1][2][3].

IC50 & Target

MMP2[1].
体外研究
(In Vitro)

GPLGIAGQ is used to trigger PEG deshielding of liposomal carriers, resulting in enhanced cellular internalization[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

825.83

Formula

C33H54F3N9O12
Sequence

Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln
Sequence Shortening

GPLGIAGQ
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (60.55 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2109 mL 6.0545 mL 12.1090 mL
5 mM 0.2422 mL 1.2109 mL 2.4218 mL
10 mM 0.1211 mL 0.6055 mL 1.2109 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.03 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.03 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.03 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Hou W, et al. MMP2-Targeting and Redox-Responsive PEGylated Chlorin e6 Nanoparticles for Cancer Near-Infrared Imaging and Photodynamic Therapy. ACS Appl Mater Interfaces. 2016 Jan 20;8(2):1447-57.

    [2]. Zhu L, et al. Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials. 2014 Apr;35(13):4213-22.

    [3]. Liu FH, et al. Enzyme-sensitive cytotoxic peptide-dendrimer conjugates enhance cell apoptosis and deep tumor penetration. Biomater Sci. 2018 Feb 27;6(3):604-613.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

JTP10-△-R9 TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

JTP10-△-R9 TFA  纯度: 99.80%

JTP10-△-R9 TFA 是选择性的 JNK2 多肽抑制剂，其 IC50 值为 89 nM，对 JNK2 的选择性是JNK1 和 JNK3 的10倍以上。

JTP10-△-R9 TFA

JTP10-△-R9 TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ￥2000 In-stock
5 mg ￥5000 In-stock
10 mg ￥8500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

JTP10-△-R9 TFA 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

JTP10-△-R9 TFA is a selective JNK2 peptide inhibitor, with an IC50 of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3[1].

IC50 & Target

JNK2

89 nM (IC50)

JNK1

1.1 μM (IC50)

JNK3

1.2 μM (IC50)

体外研究
(In Vitro)

JTP10-△-R9 TFA inhibits the migration of PyVMTjnk2+/+ cells and PyVMTjnk2-/- cells expressing GFP-JNK2α[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

2860.31

Formula

C119H214F3N53O26
Sequence

Ac-Pro-Lys-Arg-Pro-Thr-Thr-Leu-Asn-Leu-Phe-{Ahx}-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH2
Sequence Shortening

Ac-PKRPTTLNLF-{Ahx}-RRRRRRRRR-NH2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Tamer S. Kao, et al. Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. ACS Chem Biol. 2011 Jun 17;6(6):658-66.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

iRGD peptide 1 TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

iRGD peptide 1 TFA  纯度: 98.34%

iRGD peptide 1 TFA 是一种原型肿瘤特异性组织穿透肽，可将药物深深地输送到血管外肿瘤组织中，并具有抗转移活性。

iRGD peptide 1 TFA

iRGD peptide 1 TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ￥600 In-stock
5 mg ￥1500 In-stock
10 mg ￥2400 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

iRGD peptide 1 TFA 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

iRGD peptide 1 TFA is the prototypic tumor-specific tissue-penetrating peptide, which delivers drugs deep into extravascular tumor tissue. iRGD peptide 1 TFA has anti-metastatic activity[1].

体外研究
(In Vitro)

iRGD peptide 1 (iRGD) inhibits migration of tumor cells and caused chemorepulsion in vitro in a CendR- and NRP-1-dependent manner. iRGD peptide 1 induces dramatic collapse of cellular processes and partial cell detachment, resulting in the repellent activity. These effects are prominently displayed when the cells are seeded on fibronectin, suggesting a role of CendR in functional regulation of integrins[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

iRGD peptide 1 (amino acid sequence: CRGDKGPDC; 4 μmol/kg; intravenous injection; every other day; for 21 days) potently inhibits spontaneous metastasis in mice[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1064.08

Formula

C37H60F3N13O16S2
Sequence

Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys
Sequence Shortening

CRGDKGPDC
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
参考文献

  • [1]. Kazuki N Sugahara, et al. Tumor-penetrating iRGD Peptide Inhibits Metastasis. Mol Cancer Ther. 2015 Jan;14(1):120-8.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

LyP-1 TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

LyP-1 TFA  纯度: 99.36%

LyP-1 TFA 是一种环状 9 个氨基酸的肿瘤的定位肽，在多种肿瘤相关细胞中，选择性结合其 p32 receptor 蛋白。

LyP-1 TFA

LyP-1 TFA Chemical Structure

规格 价格 是否有货 数量
5 mg ￥1200 In-stock
25 mg ￥3500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

LyP-1 TFA 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library
  • Covalent Screening Library
  • Macrocyclic Compound Library
  • Peptide Library

生物活性

LyP-1 TFA is a cyclic 9‐amino‐acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells[1].

体内研究
(In Vivo)

LyP-1 TFA (8 weeks) shows a remarkable reduction in plaque formation and plaque occupation rates in the LyP-1-treated group. In addition, a higher apoptotic rate in macrophages released from hypoxic plaques is observed after the treatment of LyP-1when compared to control peptide[1].
The LyP-1 peptide is labeled with a near-infrared fluorophore (Cy5.5) for optical imaging.
At days 3, 7, 14 and 21 after inoculation with 4T1 cells, tumor-bearing BALB/C mice is injected Cy5.5-LyP-1 (0.8 nmol) through the middle phalanges of the upper extremities of the tumor-bearing mice. The fluorescence intensities were 0.024, 0.038, 0.048 and 0.106×106 photon/cm2/sec respectively at days 3, 7, 14 and 21 after tumor cell inoculation, which are 1.02, 1.63, 2.04, and 4.52-fold higher than in the contralateral LNs. Cy5.5-LyP-1 staining in LNs co-localized with LYVE-1, suggesting lymphatics-specific binding of LyP-1 peptide[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1106.16

Formula

C38H66F3N17O14S2
Sequence Shortening

CGNKRTRGC (Disulfide bridge: Cys1-Cys9)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (90.40 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9040 mL 4.5201 mL 9.0403 mL
5 mM 0.1808 mL 0.9040 mL 1.8081 mL
10 mM 0.0904 mL 0.4520 mL 0.9040 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.26 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.26 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.26 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.26 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.26 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.26 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Fan Zhang, et al.Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide. Amino Acids. 2012 Jun;42(6):2343-51.

    [2]. Ningning Song, et al. Recent progress in LyP-1-based strategies for targeted imaging and therapy. Drug Deliv. 2019 Dec;26(1):363-375.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Aminobenzenesulfonic auristatin E TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Aminobenzenesulfonic auristatin E TFA 

Aminobenzenesulfonic auristatin E TFA 是抗体偶联药物的一部分，由细胞毒性微管蛋白修饰剂 Auristatin E 和 ADC linker Aminobenzenesulfonic 连接而成。

Aminobenzenesulfonic auristatin E TFA

Aminobenzenesulfonic auristatin E TFA Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Aminobenzenesulfonic auristatin E TFA is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1].

IC50 & Target

Auristatin

 

体外研究
(In Vitro)

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

867.03

Formula

C39H65F3N6O10S
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Kevin HAMBLETT, et al. Anti-her2 biparatopic antibody-drug conjugates and methods of use.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA(Synonyms: Cereblon Ligand-Linker Conjugates 12 TFA; E3 Ligase Ligand-Linker Conjugates 23 TFA)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA (Synonyms: Cereblon Ligand-Linker Conjugates 12 TFA; E3 Ligase Ligand-Linker Conjugates 23 TFA)

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA 是一种合成的 E3 连接酶配体-linker 偶联物，包含基于 Thalidomide 的 cereblon 配体和 3 个单元 PEG linker。

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA(Synonyms: Cereblon Ligand-Linker Conjugates 12 TFA; E3 Ligase Ligand-Linker Conjugates 23 TFA)

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA Chemical Structure

CAS No. : 2435572-49-7

规格 价格 是否有货
50 mg ￥6500 询问价格 & 货期
100 mg ￥9800 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

IC50 & Target

Cereblon

 

分子量

648.58

Formula

C27H35F3N4O11
CAS 号

2435572-49-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Deltasonamide 2 (TFA)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Deltasonamide 2 (TFA)  纯度: 99.65%

Deltasonamide 2 TFA 是一种竞争性的，高亲和力的 PDEδ 抑制剂，Kd 值约为 385 pM。

Deltasonamide 2 (TFA)

Deltasonamide 2 (TFA) Chemical Structure

CAS No. : 2235358-74-2

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥4606 In-stock
5 mg ￥3500 In-stock
10 mg ￥5500 In-stock
50 mg ￥16500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Deltasonamide 2 (TFA) 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Anti-Alzheimer’s Disease Compound Library
  • Neurodegenerative Disease-related Compound Library
  • Targeted Diversity Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Deltasonamide 2 TFA is competitive, high affinity PDEδ inhibitor with a Kd of ~385 pM[1].

IC50 & Target

Kd: ~385 pM (PDEδ)[1]
分子量

761.27

Formula

C32H40ClF3N6O6S2
CAS 号

2235358-74-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (164.20 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.3136 mL 6.5680 mL 13.1359 mL
5 mM 0.2627 mL 1.3136 mL 2.6272 mL
10 mM 0.1314 mL 0.6568 mL 1.3136 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (2.73 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (2.73 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (2.73 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (2.73 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Klein CH, et al. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell linesharboring oncogenic KRas. Int J Cancer. 2019 Feb 15;144(4):767-776.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Antioxidant peptide A TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Antioxidant peptide A TFA  纯度: 99.35%

Antioxidant peptide A TFA 是一种短肽。作用于癌细胞时，Antioxidant peptide A 的侧链有助于增强自由基清除活性。

Antioxidant peptide A TFA

Antioxidant peptide A TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ￥900 In-stock
5 mg ￥2700 In-stock
10 mg ￥4400 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Antioxidant peptide A TFA 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library
  • Covalent Screening Library
  • Peptide Library

生物活性

Antioxidant peptide A TFA is a short peptide, which contains alternative aromatic or sulfur-containing amino acid. The side chains of Antioxidant peptide A are believed to contribute to strong radical scavenging activities of peptides in the cancer cell[1].

分子量

884.99

Formula

C33H55F3N12O9S2
Sequence

Pro-His-Cys-Lys-Arg-Met
Sequence Shortening

PHCKRM
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Kalmodia S, et al. Bio-conjugation of antioxidant peptide on surface-modified gold nanoparticles: a novel approach to enhance the radical scavenging property in cancer cell. Cancer Nanotechnol. 2016;7:1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务